Verrica Pharmaceuticals Inc [NASDAQ: VRCA] loss -5.28% on the last trading session, reaching $2.33 price per share at the time.
If compared to the average trading volume of 467.19K shares, VRCA reached a trading volume of 2573018 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Here is what top equities market gurus are saying about Verrica Pharmaceuticals Inc [VRCA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VRCA shares is $14.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VRCA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Needham have made an estimate for Verrica Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 25, 2023. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on March 22, 2023, representing the official price target for Verrica Pharmaceuticals Inc stock. Previously, the target price had yet another raise from $4 to $11, while RBC Capital Mkts kept a Outperform rating on VRCA stock. On May 25, 2022, analysts decreased their price target for VRCA shares from 16 to 4.
The Average True Range (ATR) for Verrica Pharmaceuticals Inc is set at 0.48, with the Price to Sales ratio for VRCA stock in the period of the last 12 months amounting to 7.15.
Trading performance analysis for VRCA stock
Verrica Pharmaceuticals Inc [VRCA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -19.93. With this latest performance, VRCA shares dropped by -65.17% in over the last four-week period, additionally sinking by -59.27% over the last 6 months – not to mention a drop of -48.39% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VRCA stock in for the last two-week period is set at 18.32, with the RSI for the last a single of trading hit 14.33, and the three-weeks RSI is set at 22.76 for Verrica Pharmaceuticals Inc [VRCA]. The present Moving Average for the last 50 days of trading for this stock 6.09, while it was recorded at 2.59 for the last single week of trading, and 6.09 for the last 200 days.
Verrica Pharmaceuticals Inc [VRCA]: A deeper dive into fundamental analysis
Verrica Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.23 and a Current Ratio set at 2.36.
Verrica Pharmaceuticals Inc [VRCA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Verrica Pharmaceuticals Inc posted -0.54/share EPS, while the average EPS was predicted by analysts to be reported at -0.36/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.18. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VRCA.
An analysis of Institutional ownership at Verrica Pharmaceuticals Inc [VRCA]
There are presently around $43.79%, or 66.89%% of VRCA stock, in the hands of institutional investors. The top three institutional holders of VRCA stocks are: PERCEPTIVE ADVISORS LLC with ownership of 7.1 million shares, which is approximately 15.2724%. AVORO CAPITAL ADVISORS LLC, holding 4.0 million shares of the stock with an approximate value of $$29.16 million in VRCA stocks shares; and AVORO CAPITAL ADVISORS LLC, currently with $$9.25 million in VRCA stock with ownership which is approximately 2.731%.
